Announced Thu, 18 Jun · 09:52 IST
P&G Health shares Investor Presentation; FY26 sales up 16%, PAT up 30%
Investor Communications View source PDF
PGHL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+1.6%1-day move
₹6220.00
prior close
₹6276.00
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.1-0.1+0.1-0.0+1.6+1.3-0.3+0.5+0.3+1.6+9.5+9.9——
Up moveDown movePending
AI summary
Procter & Gamble Health filed its investor presentation for the June 18, 2026 analyst meet. FY25-26 sales rose 16% and PAT jumped 30%, with 5-year net sales CAGR of 7% and PAT CAGR of 13%. Revenue grew from INR 1,008 Cr (2021) to 1,408 Cr (2026). Strategy focuses on portfolio superiority, productivity savings of INR 35 Cr, and expansion into extra-urban and e-commerce channels. New launches include Livogen Iron Gummies and Neurobion Pain Cream.
Likely market impact
Strong FY26 results and clear growth strategy may boost investor confidence. New product launches and channel expansion support future growth.